Positive Expression of NEDD9 in Head and Neck Cancer Is Related to Better Survival Period

Abstract

The aim was to determine immunohistochemical expression of NEDD9 protein in head and neck squamous cell carcinoma (HNSCC) and the possible relation of its expression with primary tumor size (T), regional lymph node status (N), stage of disease (TNM) and survival period. A total of 131 patients with primary tumor localization in the area of oropharynx, hypopharynx and larynx, monitored for at least 5 years after initial surgical treatment were analyzed. The study included 128 male and three female patients, median age 62.0 (range 53.0-68.0) years. Of these, 105 (95%) patients showed positive NEDD9 expressed by dyed cytoplasm. There were no significant differences in NEDD9 expression according to TNM tumor status. Patients with positive NEDD9 expression had a significantly higher median (IQR) survival time 51.0 (15.0-60.0) months as compared to 22.5 (9.0-55.0) months in patients with negative NEDD9 expression (p=0.048). NEDD9 negative expression, controlled for the influence of other variables included in the Cox's proportional hazards model, had a significant hazard ratio (HR) of 2.10 (95% CI: 1.23-3.58; p=0.006). The results of our study showed that NEDD9 expression might be an independent prognostic marker in patients with HNSCC regarding data on overall survival and mortality.

Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing

“…The hub-protein ZFP36 is associated with breast cancer and tumor-suppressive actions during hepatic tumor progression 94,95 . The hub-protein NEDD9 is significantly associated with head and neck and lung cancers 96,97 . The hub-protein KLF6 has a direct involvement in ovarian cancer cell proliferation and metastasis promotion and also works as a critical regulator of pathogenic myeloid cell activation in human 98,99 .…”

Clinical Course of the Disease and Treatment Outcome in Patients with Malignant Laryngeal Tumor: Retrospective Five-Year Analysis

“…The approach to treating malignant laryngeal tumors can be surgical, oncologic or combined. Despite significant progress in treatment, a significant decrease in the 5-year survival rate has been recorded in the last few decades ( 2 , 3 ). In the 1975-1977 period, the 5-year survival rate was 66%, whereas in the 2005-2011 period it dropped to 63% ( 4 ).…”